Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1763-1767

  Perdigao Neto L V ^a   Oliveira, M S ^a   Rizek, C F ^a   Carrilho, C M D M ^b   Costa, S F ^a   Levin, A S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN;

ACINETOBACTER BAUMANNII; AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; DISK DIFFUSION; ENTEROBACTER; ENTEROBACTERIACEAE; EPSILOMETER TEST; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTER; ENTEROBACTERIACEAE; FOSFOMYCIN; GRAM-NEGATIVE BACTERIA; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 84896870182     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02048-13     Document Type: Article

References (25)

1. Fritsche TR, Sader HS, Toleman MA, Walsh TR, Jones RN. 2005. Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program. Clin. Infect. Dis. 41:276-278.
2. Rice LB. 2012. Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones. Mayo Clin. Proc. 87:198-208. http://dx.doi.org/10.1016/j.mayocp.2011.12.003.
3. Cantón R, Lumb J. 2011. Emerging resistance in Gram-negative pathogens and implications for clinical practice. Future Microbiol. 6:19-22. http://dx.doi.org/10.2217/fmb.10.150.
4. Cai Y, Wang R, Liang B, Bai N, Liu Y. 2011. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob. Agents Chemother. 55:1162-1172. http://dx.doi.org/10.1128/AAC.01402-10.
5. Blot S, De Waele JJ, Vogelaers D. 2012. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs 72:e17- e32. http://dx.doi.org/10.2165/11599800-000000000-00000.
6. Wagenlehner FM, Wullt B, Perletti G. 2011. Antimicrobials in urogenital infections. Int. J. Antimicrob. Agents 38:3-10. http://dx.doi.org/10.1016/j. ijantimicag.2011.09.004.
7. Michalopoulos AS, Livaditis IG, Gougoutas V. 2011. The revival of fosfomycin. Int. J. Infect. Dis. 11:e732- e739.
8. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. 2008. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis. 46:1069-1077. http://dx.doi.org/10.1086/527442. (Pubitemid 351589875)
9. Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas ME. 2009. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob. Agents Chemother. 53:4508-4510. http://dx.doi.org/10.1128/AAC.00721- 09.
10. Neuner EA, Sekeres J, Hall GS, van Duin D. 2012. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob. Agents Chemother. 56:5744-5748. http://dx.doi.org/10. 1128/AAC.00402-12.
11. Karageorgopoulos DE, Wang R, Yu W, Falagas ME. 2012. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J. Antimicrob. Chemother. 67:255-268. http://dx.doi.org/10.1093/jac/dkr466.
12. Pasteran F, Lucero C, Rapoport M, Guerriero L, Barreiro I, Albornoz E, Veliz O, Corso A. 2012. Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae. J. Infect. Dev. Ctries. 6:452-456.
13. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
14. European Committee on Antimicrobial Susceptibility Testing. 2012. European Committee on Antimicrobial Susceptibility Testing clinical breakpoints. http://www.eucast.org/clinical-breakpoints. Accessed 1 December 2012.
15. Mostachio AK, Levin AS, Rizek C, Rossi F, Zerbini J, Costa SF. 2012. High prevalence of OXA-143 and alteration of outer membrane proteins in carbapenem-resistant Acinetobacter spp. isolates in Brazil. Int. J. Antimicrob. Agents 39:396-401. http://dx.doi.org/10.1016/j.ijantimicag.2012.01.021.
16. Rasheed JK, Biddle JW, Anderson KF, Washer L, Chenoweth C, Perrin J, Newton DW, Patel JB. 2008. Detection of the Klebsiella pneumoniae carbapenemase type 2 carbapenem-hydrolyzing enzyme in clinical isolates of Citrobacter freundii and K. oxytoca carrying a common plasmid. J. Clin. Microbiol. 46:2066-2069. http://dx.doi.org/10.1128/JCM.02038-07. (Pubitemid 351831844)
17. Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters; approved guidelines M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Endimiani A, Patel G, Hujer KM, Swaminathan M, Perez F, Rice LB, Jacobs MR, Bonomo RA. 2010. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob. Agents Chemother. 54:526-529. http://dx.doi.org/10. 1128/AAC.01235-09.
19. Lu CL, Liu CY, Huang YT, Liao CH, Teng LJ, Turnidge JD, Hsueh PR. 2011. Antimicrobial susceptibilities of commonly encountered bacterial isolates to Fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob. Agents Chemother. 55:4295-4301. http://dx.doi.org/10.1128/AAC.00349-11.
20. Goto M, Sugiyama M, Nakajima S, Yamashina H. 1981. Fosfomycin kinetics after intravenous and oral administration to human volunteers. Antimicrob. Agents Chemother. 20:393-397. http://dx.doi.org/10.1128/AAC.20.3.393. (Pubitemid 12225720)
21. Lastra CF, Mariño EL, Barrueco M, Gervós MS, Gil AD. 1984. Disposition of phosphomycin in patients with pleural effusion. Antimicrob. Agents Chemother. 25:458-462. http://dx.doi.org/10.1128/AAC.25.4.458.
22. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. 2009. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int. J. Antimicrob. Agents 34:506-515. http://dx.doi.org/10.1016/j.ijantimicag.2009.08. 013.
23. Schintler MV, Traunmüller F, Metzler J, Kreuzwirt G, Spendel S, Mauric O, Popovic M, Scharnagl E, Joukhadar C. 2009. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J. Antimicrob. Chemother. 64:574-578. http://dx.doi.org/10.1093/jac/dkp230.
24. Díez-Aguilar M, Morosini MI, Campo R, García-Castillo M, Zamora J, Cantón R. 2013. In vitro activity of fosfomycin against a collection of clinical Pseudomonas aeruginosa isolates from 16 Spanish hospitals: establishing the validity of standard broth microdilution as susceptibility testing method. Antimicrob. Agents Chemother. 57:5701-5703. http://dx.doi.org/10.1128/AAC.00589-13.
25. Pereira GH, Garcia DO, Mostardeiro M, Ogassavara CT, Levin AS. 2011. Spread of carbapenem-resistant Klebsiella pneumoniae in a tertiary hospital in Sao Paulo, Brazil. J. Hosp. Infect. 79:182-183. http://dx.doi.org/10.1016/j. jhin.2011.05.023.